Literature DB >> 14564689

Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice.

Toshihiro Takahashi1, Tsutomu Hirano, Kenta Okada, Mitsuru Adachi.   

Abstract

To explore the role of apolipoprotein (apo) CIII in the development of hypertriglyceridemia associated with diabetes mellitus, we examined triglyceride (TG) kinetics in apo CIII - deficient mice (apo CIII - null) and wild-type (WT) (C57BL/6J) mice with diabetes induced by the injection of streptozotocin (STZ). Plasma TG levels increased significantly in WT mice after diabetes was induced (102 +/- 29 v 65 +/- 33 mg/dL, P <.01). Apo CIII-null mice had a significantly lower TG level (35 +/- 9 mg/dL) that remained unchanged even when diabetes was induced (35 +/- 8 mg/dL). The TG secretion rate (TGSR) measured by the Triton WR1339 method tended to decrease in diabetic WT, indicating that catabolism of TG was impaired. Apo CIII-null mice showed 2-fold higher TG production than WT mice, indicating markedly faster clearance of TG. The high TGSR was halved when diabetes was induced in apo CIII-null mice, and the fractional catabolic rate (FCR) of TG was also halved, although it was still significantly higher than in WT mice. Lipoprotein lipase (LPL) activity in postheparin plasma was not significantly altered in WT or apo CIII-null mice regardless of the presence or absence of diabetes. [(3)H] very-low-density lipoprotein (VLDL)-TG from WT or apo CIII-null mice showed similar clearance by WT recipients, and this was also observed when VLDL was obtained from diabetic counterparts. In contrast, VLDL-TG was cleared faster by apo CIII-null recipients compared with WT recipients, regardless of the VLDL donors. These results suggest that apo CIII deficiency prevents the development of hypertriglyceridemia associated with diabetes by stimulating TG removal, possibly by promoting the interaction of VLDL with the TG removal system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564689     DOI: 10.1016/s0026-0495(03)00202-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia.

Authors:  Rebecca A Haeusler; Seongah Han; Domenico Accili
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

2.  The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.

Authors:  Meenakshi Sundaram; Kaitlin R Curtis; Mohsen Amir Alipour; Nicholas D LeBlond; Kaitlyn D Margison; Rebecca A Yaworski; Robin J Parks; Adam D McIntyre; Robert A Hegele; Morgan D Fullerton; Zemin Yao
Journal:  J Lipid Res       Date:  2017-09-08       Impact factor: 5.922

3.  Lipoprotein genotype and conserved pathway for exceptional longevity in humans.

Authors:  Gil Atzmon; Marielisa Rincon; Clyde B Schechter; Alan R Shuldiner; Richard B Lipton; Aviv Bergman; Nir Barzilai
Journal:  PLoS Biol       Date:  2006-04-04       Impact factor: 8.029

4.  Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha).

Authors:  Eric S Tien; Daniel B Hannon; Jerry T Thompson; John P Vanden Heuvel
Journal:  PPAR Res       Date:  2006       Impact factor: 4.964

5.  Alcohol-induced Hyperlipidemia Is Ameliorated by Orally Administered DWP208, a Sodium Succinate Form of ZYM201.

Authors:  Jae Youl Cho; Jongwon Choi; Jae Gwang Park; Young-Su Yi; Muhammad Jahangir Hossen; Hyeongmin Kim; Jieun Ro; Bae Cheon Cha; Eun Sook Yoo; Jong-Hoon Kim; Jaehwi Lee
Journal:  Korean J Physiol Pharmacol       Date:  2014-12-30       Impact factor: 2.016

Review 6.  Pathophysiology of Diabetic Dyslipidemia.

Authors:  Tsutomu Hirano
Journal:  J Atheroscler Thromb       Date:  2018-07-12       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.